Atlas Trials

Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

Clinical trial NCT00205478 · COMPLETED

Trial details

NCT number
NCT00205478
Sponsor
Vertex Pharmaceuticals Incorporated
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Rheumatoid Arthritis
Start date
2005-06-01
Enrollment
300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.